Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe

What can define +MRI for active spine lesions in axSpA? *⃣ BME in >/=4 vertebral corners (VCs) *⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion *⃣BME in >/=1 VC if w/ at least 2 VC fat lesions Such cut-offs achieve >/= 95% specificity OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK

Phenotypes in axPsA per Dr. Gladman: ⭐️15% develop axial dz at 10y: # of radiographic damaged joints, periostitis, & ⬆️ESR predictive. HLA-B27 no longer predictive ⭐️Buttock pain & IBD more common in axial dz ⭐️M had more axial dz + radiographic damage #EULAR2021. @Rheumnow

Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.